UBS analyst Marc Goodman noted Mallinckrodt (MNK) sold off after losing a generic patent ruling to Praxair (PX) on its Inomax system. The analyst said Praxair's drug and system would be a competitor to Inomax, not a generic, which means it would have to compete directly with it. He said Mallinckrodt has penetrated almost all of the high risk NICUs and many have long term contracts, making Praxair's best opportunity to win new business. Given the dominant position of Inomax, it does not leave Praxair much of an opportunity, added Goodman, who reiterated his Buy rating and $70 price target on Mallinckrodt shares.